CKMT1A: A Potential Drug Target for Cancer (G548596)

Target Name: CKMT1A

NCBI ID: G548596

CKMT1A

CKMT1A: A Potential Drug Target for Cancer

CKMT1A (CKMT1B) is a gene that encodes for a protein known as CKMT1A, which is a component of the kinesin-1 protein family. CKMT1A plays a crucial role in the regulation of cell division and is often aberrantly expressed in various diseases, including cancer. As a result, CKMT1A has become a focus of interest for researchers as a potential drug target or biomarker.

The kinesin-1 gene family is a member of the TATA-binding protein (TBP) family, which is known for regulating gene expression and DNA replication in various organisms. The kinesin-1 gene family includes four genes, CKMT1A, CKMT1B, CKMT1C, and CKMT1D. These genes encode for proteins that share a conserved catalytic core and a N-terminal hypervariable region (HVR), which is responsible for the unique structure and function of each gene product.

CKMT1A is a 21-kDa protein that is expressed in various tissues and cells, including muscle, liver, and brain. It is involved in the regulation of cell cycle progression, DNA replication, and apoptosis. CKMT1A has been shown to play a role in the regulation of cell division in various cell types and has been implicated in the development and progression of various diseases, including cancer.

One of the most significant functions of CKMT1A is its role in regulating the dynamics of microtubules in the cytosol. Microtubules are important structures that play a central role in the regulation of cell division and transport of various cellular processes within the cytosol. CKMT1A is known to interact with microtubules and is involved in the regulation of their dynamics, which is critical for the proper functioning of the cell.

In addition to its role in regulating microtubule dynamics, CKMT1A is also involved in the regulation of DNA replication. DNA replication is a critical process that is essential for the growth and development of all living organisms. CKMT1A has been shown to play a role in the regulation of DNA replication and has been implicated in the development of various diseases, including cancer.

CKMT1A has also been shown to be involved in the regulation of apoptosis, which is a process that is essential for the removal of damaged or dysfunctional cells from the body. Apoptosis is a natural process that is regulated by various factors, including CKMT1A.

The potential drug target status of CKMT1A is due to its involvement in various diseases, including cancer. Cancer is a disease that is characterized by the uncontrolled growth and proliferation of cells, which can lead to the development of various tumors. CKMT1A has been shown to be involved in the regulation of cell division and has been implicated in the development of various cancers, including breast, ovarian, and colorectal cancers. As a result, CKMT1A has become a focus of interest for researchers as a potential drug target or biomarker.

In conclusion, CKMT1A is a gene that encodes for a protein that is involved in the regulation of cell division, DNA replication, and apoptosis. Its unique structure and function make it a potential drug target or biomarker for various diseases, including cancer. Further research is needed to fully understand the role of CKMT1A in the regulation of cell division and the development of various diseases.

Protein Name: Creatine Kinase, Mitochondrial 1A

Functions: Reversibly catalyzes the transfer of phosphate between ATP and various phosphogens (e.g. creatine phosphate). Creatine kinase isoenzymes play a central role in energy transduction in tissues with large, fluctuating energy demands, such as skeletal muscle, heart, brain and spermatozoa

The "CKMT1A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CKMT1A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets